Acurx Pharmaceuticals (ACXP) Proxy filing summary

Executive summary

• The 2026 annual meeting will be held virtually on October 16, 2026, allowing shareholders to attend, vote, and ask questions online, with the aim of increasing participation and reducing costs and environmental impact.

• Shareholders of record as of August 20, 2026, are eligible to vote on the election of two Class II directors and the ratification of the independent auditor.

• Proxy materials are distributed primarily via the internet, with options for paper copies upon request, to conserve resources and lower costs.

Voting matters and shareholder proposals

• Shareholders will vote on electing two Class II directors for three-year terms expiring in 2029 and ratifying CohnReznick LLP as the independent registered public accounting firm for 2026.

• The board recommends voting in favor of both proposals.

• Shareholders may submit proposals for the 2027 annual meeting by specified deadlines.

Board of directors and corporate governance

• The board consists of seven members divided into three classes, with staggered three-year terms.

• Five directors are considered independent under Nasdaq rules.

• The board separates the roles of executive chairman and CEO to enhance oversight and governance.

• Committees include Audit and Compensation, both composed entirely of independent directors.

• No standing nominating committee; independent directors recommend nominees.